Introduction
============

CRC is the third most common malignancy and the fourth leading cause of mortality worldwide.[@b1-cmar-10-4051] Risk stratification of CRC may require the combined multiple approaches, including analysis of molecular biomarkers and clinical data, and thorough experimental studies. In the past two decades, study results have confirmed that tumor is a heterogeneity disease.[@b2-cmar-10-4051] The combined model of multiple clinical and molecular parameters could be a much more objective prognostic tool for CRC patients.

Chemokines are a group of small molecular weight proteins that bind to the G protein-coupled chemokine receptors.[@b3-cmar-10-4051] Chemokines and their receptors are divided into four subfamilies (CXC, CC, CX3C, and C) based on the pattern of cysteine residues, where C represents the cysteine and X represents noncysteine amino acids.[@b4-cmar-10-4051],[@b5-cmar-10-4051] Chemokine family genes are closely related with senescence, angiogenesis, epithelial mesenchymal transition, proliferation, immune evasion, and tumor metastasis.[@b6-cmar-10-4051] The altered expression of chemokines and their receptors is found in many malignancies and may lead to aberrant chemokine receptor signaling.[@b7-cmar-10-4051]--[@b20-cmar-10-4051] The chemokine ligand--receptor interactions were closely related with tumor immunity, progression, and metastasis in CRC patients, including the CXCL1-- CXCR2,[@b7-cmar-10-4051] CXCL9/10--CXCR3,[@b8-cmar-10-4051],[@b9-cmar-10-4051] CXCL12--CXCR4,[@b10-cmar-10-4051]--[@b14-cmar-10-4051] CCL2--CCR2,[@b15-cmar-10-4051],[@b16-cmar-10-4051] CCL5--CCR5,[@b17-cmar-10-4051] CCL15--CCR1,[@b18-cmar-10-4051] CCL20-- CCR6,[@b19-cmar-10-4051] and CX3CL1--CX3CR1[@b20-cmar-10-4051] axes. Although small sample studies showed that some chemokines could be used as the single biomarker for CRC, the values of these genes were not further validated in other validation sets.[@b8-cmar-10-4051],[@b11-cmar-10-4051],[@b13-cmar-10-4051],[@b16-cmar-10-4051],[@b21-cmar-10-4051]--[@b23-cmar-10-4051] Until now, there is no multi-RNA classifier of chemokine family genes for predicting tumor recurrence in CRC patients. As a widely used microarray platform, Affymetrix human genome U133 plus 2.0 array included all probes of human genome U133 set and about 6,500 new genes.[@b24-cmar-10-4051] Almost all the mRNA-level data of chemokine family genes could be obtained from this microarray platform. Laetitia Marisa defined six molecular subtypes for CRC based on the main biological characteristics, including one subtype with downregulated immune pathways (C1), one deficient mismatch repair subtype (C2), one KRAS mutant subtype (C3), one cancer stem cell subtype (C4), one subtype with the upregulated Wnt pathway (C5), and one subtype with a normal-like gene expression profile (C6).[@b25-cmar-10-4051] Therefore, we performed this study to develop and validate a multi-RNA prognostic classifier of chemokine family genes for predicting recurrence in stage I--III patients with CRC by analyzing the microarray data. These multi-RNA signatures were further validated in CRC patients with different Marisa's biological subtypes (C1--C6).[@b25-cmar-10-4051]

Materials and methods
=====================

Datasets preparation
--------------------

Gene expression of chemokine family genes and corresponding clinical data were obtained from the GEO database. All log2-transformed expression data of chemokines and their receptors were obtained from Affymetrix human genome U133 plus 2.0 array (GSE39582 and GSE14333). The expression values of genes with multiple probes were calculated by using the median values of multiple probes. After filtering out CRC patients without DFS and clinical data, there were a total of 718 stage I--III patients with CRC, including 492 from GSE39582 and 226 from GSE14333. The 492 patients from GSE39582 were randomly divided into training (n=246, GSE39582) and internal validation (n=246, GSE39582) sets. The 226 patients from GSE14333 were used for the external independent set.

Statistical analysis
--------------------

The survival analysis was performed by the "survival" package of R software (version 3.4.3). In the training set, the association between the expression level of chemokine family genes and CRC patients' DFS was evaluated using a univariate Cox regression analysis. Those chemokine family genes were considered to be significant if their *P*-values were less than 0.05. Then, the selected chemokine family genes were fitted in a multivariate Cox regression analysis in the training set. Risk scores were calculated by the selected chemokine family genes and their regression coefficients in the multivariate Cox regression analysis,[@b26-cmar-10-4051]--[@b28-cmar-10-4051] as follows: $$RiskScore = {\sum\limits_{i = 1}^{k}{C_{i} \times V_{i}}}$$where *k* is the number of prognostic chemokines, *C~i~* represents the coefficient of the *i*th chemokine in the multivariate Cox regression analysis, *V~i~* is the expression value of the *i*th chemokine. Using the upper quartile value of risk scores in the training set as the cutoff point, CRC patients in the training, internal validation, and external independent sets were classified as low-risk or high-risk correspondingly. Survival differences between low-risk and high-risk groups were assessed by the Kaplan--Meier estimator and log-rank test. The multivariate Cox regression analysis was performed to assess whether this risk score was independent of the clinical characteristics such as stage, age, gender, and adjuvant chemotherapy. Additionally, ROC curves were used to compare the predictive value of DFS by the combined model of risk score and stage, and this risk score model and stage alone. The ROC curve analysis was performed using the "pROC" package of R software (version 3.4.3). To generate the ROC curves, those CRC patients whose durations were less than the 5-year DFS needed to be excluded, if they still did not recur at last follow-up. The remaining CRC patients were classified as having either shorter or longer than the recurrence-free survival of 60 months.[@b28-cmar-10-4051] The prognostic values of this multi-RNA prognostic classifier were further validated in different Marisa's biological subtypes (C1--C6).[@b25-cmar-10-4051] The log-rank test, Cox regression analysis, and ROC analysis were considered to be significant if their *P*-values were less than 0.05.

Functional enrichment analysis
------------------------------

To evaluate the functional implication of these nine chemokines, functional enrichment analyses for GO and KEGG category were performed with the GeneCodis web tool (<http://genecodis.cnb.csic.es/>).[@b29-cmar-10-4051]--[@b31-cmar-10-4051] GO and KEGG category enrichments were based on the threshold of *P*-value \<0.05. Significant enrichment results were visualized using R software (version 3.4.3).

Results
=======

Identification of survival-related chemokines in the training set
-----------------------------------------------------------------

[Figure 1](#f1-cmar-10-4051){ref-type="fig"} shows the study flow for the development and validation of the nine-chemokine classifier. By using microarray data, we identified 59 chemokine family genes from GSE39582 and GSE14333. We further analyzed these 59 genes by the univariate Cox regression analysis in the training set (n=246, GSE39582; [Table S1](#SD1-cmar-10-4051){ref-type="supplementary-material"}). Consequently, we identified nine chemokines that were significantly correlated with DFS in CRC patients (shown in [Table 1](#t1-cmar-10-4051){ref-type="table"}). The positive coefficients for three chemokines (CCL1, CCL14, and CXCL14) indicated that their higher levels of expression were associated with worse prognosis. The negative coefficients for the remaining six genes (CXCL1, CXCL3, CXCL9, CXCL10, CXCL11, and CXCL13) indicated that their higher levels of expression were associated with better prognosis.

Survival comparisons between low-risk and high-risk groups in the training, internal validation, and external independent sets
------------------------------------------------------------------------------------------------------------------------------

According to these chemokines and their regression coefficients in the multivariate Cox model, we calculated the risk scores for every patient in the training (n=246, GSE39582), internal validation (n=246, GSE39582), and external independent (n=226, GSE14333) sets. Using the cutoff value of risk scores (1.559), CRC patients were classified into low-risk group and high-risk group for the training (low-risk/high-risk: 185/61), internal validation (low-risk/high-risk: 196/50), and external independent (low-risk/high-risk: 185/41) sets. [Figure 2](#f2-cmar-10-4051){ref-type="fig"} shows the distributions of this risk score and the DFS status in these three sets. As shown in [Figure 2](#f2-cmar-10-4051){ref-type="fig"}, CRC patients with high-risk scores tended to have higher risk of treatment relapse.

The clinical characteristics of low-risk group and high-risk group patients with CRC in these three sets are shown in [Table 2](#t2-cmar-10-4051){ref-type="table"}. There were no differences for clinical characteristics (age, gender, stage, and adjuvant chemotherapy) between low-risk group and high-risk group (all *P*\>0.05).

[Figure 3](#f3-cmar-10-4051){ref-type="fig"} and [Table 3](#t3-cmar-10-4051){ref-type="table"} show the DFS differences between high-risk and low risk groups in these three sets. The log-rank test showed that CRC patients with low-risk scores had significantly longer DFS than those with high-risk scores in the training set (HR=2.353, 95% CI=1.480--3.742, *P*\<0.001) and internal validation (HR=2.389, 95% CI=1.428--3.996, *P*\<0.001), and external independent (HR=3.244, 95% CI=1.813--5.807, *P*\<0.001) sets.

Multivariate Cox regression analysis in the training, internal validation, and external independent sets
--------------------------------------------------------------------------------------------------------

[Table 4](#t4-cmar-10-4051){ref-type="table"} shows the multivariate Cox regression analysis results of the nine-chemokine classifier, gender, age, stage, adjuvant chemotherapy, and DFS in the training, internal validation, and external independent sets. Both the nine-chemokine classifier and stages were significantly associated with CRC patients' DFS in these datasets (all *P*\<0.05).

ROC analysis in the training, internal validation, and external independent sets
--------------------------------------------------------------------------------

[Figure 4](#f4-cmar-10-4051){ref-type="fig"} shows the ROC curves for predicting DFS in the training, internal validation, and external independent sets. AUC of the nine-chemokine classifier is similar with that of stage alone in the training (0.673 vs 0.626, *P*=0.343), internal validation (0.651 vs 0.584, *P*=0.332), and external independent (0.609 vs 0.678, *P*=0.888) sets. AUC of the combined model (nine-chemokine classifier and tumor stage) may tend to be higher than that of stage alone in the training (0.727 vs 0.626, *P*=0.001), internal validation (0.668 vs 0.584, *P*=0.030), and external independent (0.704 vs 0.678, *P*=0.298) sets.

Survival analysis between low-risk and high-risk groups in the combined training and validation set
---------------------------------------------------------------------------------------------------

Using the same cutoff point (1.559), CCR patients were categorized into low-risk group (n=381) and high-risk group (n=111) in the combined training and validation set. CRC patients with low-risk scores had significantly longer DFS (HR=2.383, 95% CI=1.690--3.359, *P*\<0.001) and OS (HR=1.603, 95% CI=1.115--2.305, *P*=0.010) than those with high-risk scores (shown in [Table 5](#t5-cmar-10-4051){ref-type="table"}). [Table 6](#t6-cmar-10-4051){ref-type="table"} shows the multivariate Cox regression analysis results of the nine-chemokine classifier, gender, age, stage, adjuvant chemotherapy, and survival in the combined training and validation set (n=492, GSE39582). The multivariate Cox analysis showed that the nine-chemokine classifier was significantly associated with patients' DFS (HR=2.292, 95% CI=1.622--3.239, *P*\<0.001) and OS (HR=1.640, 95% CI=1.139--2.362, *P*=0.008; [Table 6](#t6-cmar-10-4051){ref-type="table"}). Subgroup analysis showed that stage II--III patients with low-risk scores had significantly longer DFS (*P*\<0.05) than those with high-risk scores (shown in [Figure 5](#f5-cmar-10-4051){ref-type="fig"}).

The prediction values of the nine-chemokine classifier for different biological subtypes in the combined training and validation set
------------------------------------------------------------------------------------------------------------------------------------

To verify the value of the nine-chemokine classifier, we further validated our findings in different molecular subtypes of Laetitia Marisa in the combined training and validation set (n=460, GSE39582).

We further validated the values of the nine-chemokine classifier for different biological subtypes in the combined training and validation set (n=492, GSE39582). Patients with high-risk scores had similar DFS (all *P*\>0.05) with those with low-risk scores in the subtypes C1 (one subtype with downregulated immune pathways) and C3 (one KRAS mutant subtype) (shown in [Figure 6](#f6-cmar-10-4051){ref-type="fig"}). Patients with high-risk scores had significantly shorter DFS (all *P*\>0.05) than those with low-risk scores in the subtypes C2 (one deficient mismatch repair subtype), C4 (one cancer stem cell subtype), C5 (one subtype with the upregulated Wnt pathway), and C6 (one subtype with a normal-like gene expression profile) (shown in [Figure 6](#f6-cmar-10-4051){ref-type="fig"}). But the Cox regression analysis showed that the integrated lncRNA-mRNA classifier was not significantly associated with the subtypes C1, C3, and C4 patients' DFS (all *P*≥0.05). The integrated lncRNA-mRNA classifier was an independent prognostic factor for the subtypes C2, C5, and C6 patients' DFS (all *P*\<0.05).

Functional enrichment analysis
------------------------------

To explore the functional implication of nine chemokines, we performed functional category enrichment analysis. Functional enrichment analysis showed that the nine chemokine family genes were significantly enriched in 55 GO terms and 9 KEGG pathways (shown in [Figure 7](#f7-cmar-10-4051){ref-type="fig"}). The functional categories are mainly involved in eight GO terms, including immune response (GO:0006955), inflammatory response (GO:0006954), signal transduction (GO:0007165), chemotaxis (GO:0006935), cell--cell signaling (GO:0007267), extracellular space (GO:0005615), extracellular region (GO:0005576), and chemokine activity (GO:0008009). The mainly involved KEGG pathways included cytokine--cytokine receptor interaction (KEGG:04060), chemokine signaling pathway (KEGG:04062), and toll-like receptor signaling pathway (KEGG:04620).

Discussion
==========

Although the TNM staging system is widely used as the risk stratification of CRC patients, it is insufficient in the prediction of prognosis and estimation for some patients.[@b32-cmar-10-4051],[@b33-cmar-10-4051] Conflict clinical outcomes may exist among some CRC patients with the same stage.[@b31-cmar-10-4051],[@b32-cmar-10-4051] To date, there are no clinically utilized prognostic biomarkers in CRC patients. An increasing amount of evidence demonstrates that chemokines and their receptors play an important role in tumor immunity, progression, and metastasis of CRC patients.[@b7-cmar-10-4051]--[@b20-cmar-10-4051] The discovery and application of a multiple-chemokine biomarker will promote the evaluation and identification of potential high-risky recurrence in CRC patients. To identify the prognostic chemokines, we profiled chemokines by mining the existing microarray data of Affymetrix human genome U133 plus 2.0 array. We applied a univariate Cox regression analysis to select DFS-related chemokines. Based on this data-mining method, we have developed and validated a nine-chemokine classifier. The utility of this nine-chemokine classifier may add to the prognostic value of the TNM stage system. Furthermore, the clinical application of this nine-chemokine classifier might stratify CRC patients with the same stage into low-risk and high-risk groups of recurrence after operation. CRC patients of high-risk group had shorter DFS than those of low-risk group in stage II and III patients. The nine-chemokine classifier may provide an additional biomarker for identifying potential candidates for aggressive treatment strategies. The molecular subtype should be considered before the clinical application of the prognostic signatures. Subgroup showed that the nine-chemokine classifier was not an independent prognostic factor for DFS in Marisa's C1, C3, and C4 subtypes patients. Therefore, the nine-chemokine classifier may only be applied in Marisa's C2, C5, and C6 subtypes patients.

The nine-chemokine classifier included three risky genes (CCL1, CCL14, and CXCL14) and six protective genes (CXCL1, CXCL3, CXCL9, CXCL10, CXCL11, and CXCL13). The previous study showed that high tissue levels of CXCL14 was associated with increased risk of recurrence and mortality among CRC patients.[@b34-cmar-10-4051] However, high expressions of CXCL1,CXCL9, CXCL10, and CXCL13 may be correlated with better prognosis of CRC patients.[@b23-cmar-10-4051],[@b35-cmar-10-4051]--[@b37-cmar-10-4051] Moreover, the prognostic values of these five chemokines were not further confirmed in another validation sets. The relationship of the remaining four chemokines (CCL1, CCL14, CXCL3, CXCL11) and CRC patients' prognosis should be further studied.

Although our study possessed the larger sample size for developing and validating this nine-chemokine classifier, we should acknowledge certain potential limitations. First, preliminary functional enrichment analysis indicated that the nine-chemokine classifier was mainly involved in immune response, inflammatory response, signal transduction, chemotaxis, and cell--cell signaling. But the mechanism of these nine chemokines has not been confirmed through experimental studies. Further experimental studies may provide potential therapeutic targets for CRC patients. Second, Affymetrix human genome U133 plus 2.0 array was used for obtaining the mRNA level data of chemokine family genes in this study. But the mRNA level data of some chemokines (CCL6, CCL12, CXCL7, and CXCL15) were not available in this microarray platform. The link between the mRNA levels of these chemokines and survival of CRC patients should be further investigated by experimental studies. Third, this multi-RNA classifier was only developed and validated by the mRNA-level data. The value of this multi-RNA classifier was not further confirmed by the protein-level data. Moreover, future analysis of protein level on additional independent datasets would contribute to determine the potential importance of population and geographical differences.

In conclusion, we performed a comprehensive analysis of chemokine expression levels and corresponding survival information of CRC patients. We have successfully developed and validated a nine-chemokine classifier that may be a useful prognostic biomarker for the personalized treatment. It was the first study demonstrating a link between a multiple-chemokine classifier and tumor recurrence in CRC patients. This nine-chemokine classifier may provide an effective risk stratification of disease-free survival in CRC patients with the same stage, especially for stage II--III patients. But we should acknowledge that the protein-level data of this nine-chemokine classifier should be further validated before its clinical application.

Supplementary material
======================

###### 

Univariate Cox regression analysis of chemokine family genes associated with disease-free survival in the training set (n=246, GSE39582)

  Gene symbol   Type       Sub-family   HR (95% CI)            Coefficient   *P*-value
  ------------- ---------- ------------ ---------------------- ------------- -----------
  *CCL1*        Ligand     CC           2.729 (1.118--6.662)   1.004         0.027
  *CCL2*        Ligand     CC           1.169 (0.970--1.410)   0.156         0.102
  *CCL3*        Ligand     CC           1.004 (0.844--1.194)   0.004         0.962
  *CCL4*        Ligand     CC           1.019 (0.823--1.261)   0.019         0.863
  *CCL5*        Ligand     CC           0.918 (0.757--1.114)   −0.085        0.387
  *CCL7*        Ligand     CC           1.118 (0.728--1.719)   0.112         0.610
  *CCL8*        Ligand     CC           0.993 (0.830--1.190)   −0.007        0.943
  *CCL11*       Ligand     CC           1.019 (0.868--1.196)   0.018         0.822
  *CCL13*       Ligand     CC           1.152 (0.743--1.784)   0.141         0.527
  *CCL14*       Ligand     CC           1.400 (1.043--1.879)   0.336         0.025
  *CCL15*       Ligand     CC           1.051 (0.823--1.344)   0.050         0.688
  *CCL16*       Ligand     CC           1.556 (0.916--2.643)   0.442         0.102
  *CCL17*       Ligand     CC           1.240 (0.699--2.203)   0.215         0.462
  *CCL18*       Ligand     CC           0.987 (0.853--1.142)   −0.013        0.861
  *CCL19*       Ligand     CC           1.063 (0.902--1.252)   0.061         0.467
  *CCL20*       Ligand     CC           0.885 (0.771--1.015)   −0.122        0.082
  *CCL21*       Ligand     CC           1.124 (0.924--1.366)   0.117         0.242
  *CCL22*       Ligand     CC           0.877 (0.538--1.430)   −0.131        0.600
  *CCL23*       Ligand     CC           1.211 (0.701--2.090)   0.191         0.492
  *CCL24*       Ligand     CC           1.132 (0.919--1.395)   0.124         0.243
  *CCL25*       Ligand     CC           0.739 (0.466--1.172)   −0.302        0.199
  *CCL26*       Ligand     CC           0.938 (0.705--1.250)   −0.064        0.664
  *CCL27*       Ligand     CC           1.507 (0.673--3.373)   0.410         0.319
  *CCL28*       Ligand     CC           1.058 (0.821--1.363)   0.056         0.664
  *CXCL1*       Ligand     CXC          0.824 (0.697--0.974)   −0.194        0.024
  *CXCL2*       Ligand     CXC          0.870 (0.608--1.243)   −0.140        0.444
  *CXCL3*       Ligand     CXC          0.836 (0.708--0.986)   −0.179        0.034
  *CXCL5*       Ligand     CXC          0.939 (0.824--1.071)   −0.062        0.349
  *CXCL6*       Ligand     CXC          0.951 (0.810--1.115)   −0.051        0.534
  *CXCL8*       Ligand     CXC          0.933 (0.810--1.073)   −0.070        0.329
  *CXCL9*       Ligand     CXC          0.840 (0.722--0.977)   −0.174        0.024
  *CXCL10*      Ligand     CXC          0.832 (0.712--0.972)   −0.184        0.021
  *CXCL11*      Ligand     CXC          0.878 (0.774--0.995)   −0.131        0.041
  *CXCL12*      Ligand     CXC          1.107 (0.907--1.352)   0.102         0.319
  *CXCL13*      Ligand     CXC          0.870 (0.763--0.992)   −0.140        0.037
  *CXCL14*      Ligand     CXC          1.146 (1.008--1.302)   0.136         0.037
  *CXCL16*      Ligand     CXC          0.901 (0.650--1.249)   −0.104        0.531
  *CXCL17*      Ligand     CXC          0.814 (0.525--1.262)   −0.206        0.357
  *XCL1*        Ligand     XC           0.923 (0.524--1.627)   −0.080        0.782
  *XCL2*        Ligand     XC           1.004 (0.744--1.355)   0.004         0.978
  *CX3CL1*      Ligand     CX3C         0.896 (0.613--1.312)   −0.109        0.574
  *CCR1*        Receptor   CC           1.079 (0.786--1.481)   0.076         0.638
  *CCR2*        Receptor   CC           0.965 (0.632--1.475)   −0.035        0.870
  *CCR3*        Receptor   CC           1.001 (0.553--1.815)   0.001         0.996
  *CCR4*        Receptor   CC           1.356 (0.600--3.062)   0.304         0.464
  *CCR5*        Receptor   CC           0.861 (0.595--1.244)   −0.15         0.425
  *CCR6*        Receptor   CC           0.937 (0.622--1.411)   −0.065        0.756
  *CCR7*        Receptor   CC           0.880 (0.667--1.161)   −0.128        0.364
  *CCR8*        Receptor   CC           1.127 (0.429--2.960)   0.119         0.808
  *CCR9*        Receptor   CC           1.190 (0.391--3.620)   0.174         0.759
  *CCR10*       Receptor   CXC          1.239 (0.880--1.745)   0.214         0.220
  CXCR1         Receptor   CXC          0.511 (0.211--1.240)   −0.671        0.138
  CXCR2         Receptor   CXC          1.005 (0.746--1.355)   0.005         0.973
  CXCR3         Receptor   CXC          0.732 (0.373--1.438)   −0.312        0.365
  CXCR4         Receptor   CXC          0.979 (0.793--1.208)   −0.021        0.842
  CXCR5         Receptor   CXC          0.966 (0.412--2.267)   −0.034        0.937
  CXCR6         Receptor   CXC          0.803 (0.490--1.317)   −0.219        0.385
  XCR1          Receptor   XC           1.648 (0.515--5.274)   0.499         0.400
  CX3CR1        Receptor   CX3C         1.569 (0.864--2.849)   0.45          0.139
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![Study flow for the development and validation of the nine-chemokine classifier.\
**Abbreviation:** CRC, colorectal cancer.](cmar-10-4051Fig1){#f1-cmar-10-4051}

![The distributions of risk score and DFS status in the training (n=246, GSE39582), internal validation (n=246, GSE39582), and external independent (n=226, GSE14333) sets.\
**Abbreviation:** DFS, disease-free survival.](cmar-10-4051Fig2){#f2-cmar-10-4051}

![Kaplan--Meier curves of disease-free survival according to the nine-chemokine classifier in the training (n=246, GSE39582), internal validation (n=246, GSE39582), and external independent (n=226, GSE14333) sets.](cmar-10-4051Fig3){#f3-cmar-10-4051}

![Receiver operating characteristics curves of the combined model of the nine-chemokine classifier and stage, the nine-chemokine classifier and stage alone for predicting disease-free survival in the training (n=246, GSE39582), internal validation (n=246, GSE39582), and external independent (n=226, GSE14333) sets.\
**Abbreviation:** AUC, area under the curve.](cmar-10-4051Fig4){#f4-cmar-10-4051}

![Kaplan--Meier curves of disease-free survival according to the nine-chemokine classifier for different stage patients with CRC in the combined training and validation set (n=492, GSE39582).\
**Abbreviation:** CRC, colorectal cancer.](cmar-10-4051Fig5){#f5-cmar-10-4051}

![Kaplan--Meier curves of disease-free survival according to the nine-chemokine classifier for different biological subtypes in the combined training and validation set (n=492, GSE39582).](cmar-10-4051Fig6){#f6-cmar-10-4051}

![Results of functional enrichment analyses for GO (**A**) and KEGG (**B**) category.](cmar-10-4051Fig7){#f7-cmar-10-4051}

###### 

The characteristics of nine chemokines associated with DFS in the training set of 246 CRC patients (n=246, GSE39582)

  Gene symbol   Type     HR (95% CI)            Coefficients   *P*-value   Putative function
  ------------- -------- ---------------------- -------------- ----------- -------------------
  *CCL1*        Ligand   2.729 (1.118--6.662)   1.004          0.027       Risky
  *CCL14*       Ligand   1.400 (1.043--1.879)   0.336          0.025       Risky
  *CXCL1*       Ligand   0.824 (0.697--0.974)   −0.194         0.024       Protective
  *CXCL3*       Ligand   0.836 (0.708--0.986)   −0.179         0.034       Protective
  *CXCL9*       Ligand   0.840 (0.722--0.977)   −0.174         0.024       Protective
  *CXCL10*      Ligand   0.832 (0.712--0.972)   −0.184         0.021       Protective
  *CXCL11*      Ligand   0.878 (0.774--0.995)   −0.131         0.041       Protective
  *CXCL13*      Ligand   0.870 (0.763--0.992)   −0.140         0.037       Protective
  *CXCL14*      Ligand   1.146 (1.008--1.302)   0.136          0.037       Risky

**Abbreviation:** CRC, colorectal cancer.

###### 

Clinical characteristics of CRC patients according to the nine-chemokine classifier in the training (n=246, GSE39582), internal validation (n=246, GSE39582), and external independent (n=226, GSE14333) sets

  Characteristics         Training set (n= 246, GSE39582)   Internal validation set (n=246, GSE39582)   External independent set (n =226, GSE14333)                                 
  ----------------------- --------------------------------- ------------------------------------------- --------------------------------------------- ---- ----- ------- ---- ----- -------
  Age (years)                                                                                                                                                                       
   \<66                   30                                68                                          0.085                                         17   72    0.719   20   81    0.560
   ≥66                    31                                117                                                                                       33   124           21   104   
  Gender                                                                                                                                                                            
   Male                   32                                105                                         0.558                                         29   106   0.644   26   94    0.143
   Female                 29                                80                                                                                        21   89            15   91    
  Stage                                                                                                                                                                             
   I                      3                                 14                                          0.727                                         1    13    0.331   3    38    0.122
   II                     33                                102                                                                                       24   101           18   76    
   III                    25                                69                                                                                        25   82            20   71    
  Adjuvant chemotherapy                                                                                                                                                             
   Yes                    28                                67                                          0.078                                         24   83    0.472   21   118   0.135
   No                     32                                118                                                                                       26   113           20   67    
   Unknown                1                                 0                                                                                         0    0             0    0     

**Abbreviation:** CRC, colorectal cancer.

###### 

Log-rank test of disease-free survival according to the nine-chemokine classifier in the training (n=246, GSE39582), internal validation (n=246, GSE39582), and external independent (n=226, GSE14333) sets

  Datasets                  Risk group (n)     Disease-free survival                                          
  ------------------------- ------------------ ----------------------- ------- ------- ---------------------- ---------
  Training set (n=246)      High-risk (n=61)   91.0%                   55.9%   50.1%   2.353 (1.480--3.742)   \<0.001
                            Low-risk (n=185)   92.6%                   80.2%   74.8%                          
  Validation set (n=246)    High-risk (n=50)   77.5%                   55.4%   55.4%   2.389 (1.428--3.996)   \<0.001
                            Low-risk (n=196)   90.4%                   79.0%   75.5%                          
  Independent set (n=226)   High-risk (n=41)   84.7%                   56.5%   56.5%   3.244 (1.813--5.807)   \<0.001
                            Low-risk (n=185)   95.0%                   84.9%   80.7%                          

###### 

Multivariate Cox regression analysis of the nine-chemokine classifier, gender, age, stage, adjuvant chemotherapy, and disease-free survival in the training (n=246, GSE39582), internal validation (n=246, GSE39582), and external independent (n=226, GSE14333) sets

  Datasets                  Variable                                        Disease-free survival   
  ------------------------- ----------------------------------------------- ----------------------- ---------
  Training set (n=246)      Nine-chemokine classifier (high- vs low-risk)   2.107 (1.313--3.382)    0.002
                            Age (≥66 years vs \<66 years)                   0.944 (0.567--1.571)    0.824
                            Gender (female vs male)                         1.023 (0.644--1.626)    0.923
                            Tumor stage (III vs II vs I)                    1.763 (1.083--2.869)    0.023
                            Adjuvant chemotherapy (unknown/no vs yes)       0.761 (1.425--1.362)    0.358
  Validation set (n=246)    Nine-chemokine classifier (high- vs low-risk)   2.298 (1.370--3.855)    0.002
                            Age (≥66 years vs \<66 years)                   1.181 (0.695--2.004)    0.538
                            Gender (female vs male)                         0.624 (0.377--1.035)    0.068
                            Tumor stage (III vs II vs I)                    2.001 (1.186--3.378)    0.009
                            Adjuvant chemotherapy (unknown/no vs yes)       1.296 (0.726--2.317)    0.380
  Independent set (n=226)   Nine-chemokine classifier (high- vs low-risk)   2.914 (1.599--5.311)    \<0.001
                            Age (≥66 years vs \<66 years)                   0.666 (0.374--1.186)    0.167
                            Gender (female vs male)                         1.102 (0.621--1.954)    0.740
                            Tumor stage (III vs II vs I)                    3.235 (1.845--5.673)    \<0.001
                            Adjuvant chemotherapy (no vs yes)               0.672 (0.350--1.290)    0.232

###### 

Comparison of the survival of colorectal cancer patients according to the nine-chemokine classifier in the combined training and validation set (n=492, GSE39582)

  Set                        Risk group (n)      Disease-free survival   Overall survival                                                                               
  -------------------------- ------------------- ----------------------- ------------------ ---------------- ------- --------- ------- ------- ---------------- ------- -------
  The combined set (n=492)   High-risk (n=111)   79.8%                   55.6%              52.3%            2.383   \<0.001   93.6%   77.1%   63.5%            1.603   0.010
  Low-risk (n=381)           90.7%               79.6%                   75.2%              (1.690--3.359)           96.5%     85.2%   76.1%   (1.115--2.305)           

###### 

Multivariate Cox regression analysis of the nine-chemokine classifier, gender, age, stage, adjuvant chemotherapy, and survival in the combined training and validation set (n=492, GSE39582)

  Datasets                                    Variable                                        Disease-free survival   Overall survival                              
  ------------------------------------------- ----------------------------------------------- ----------------------- ---------------------- ---------------------- -------
  The combined set (n=492)                    Nine-chemokine classifier (high- vs low-risk)   2.292 (1.622--3.239)    \<0.001                1.640 (1.139--2.362)   0.008
  Age (≥66 years vs \<66 years)               1.019 (0.714--1.454)                            0.919                   1.395 (0.967--2.031)   0.075                  
  Gender (female vs male)                     0.806 (0.573--1.132)                            0.213                   0.768 (0.549--1.074)   0.122                  
  Tumor stage (III vs II vs I)                1.867 (1.303--2.674)                            0.001                   1.122 (0.804--1.565)   0.497                  
  Adjuvant chemotherapy (unknown/no vs yes)   0.995 (0.662--1.495)                            0.980                   1.198 (0.798--1.796)   0.384                  

[^1]: These authors contributed equally to this work
